Novo Holdings REPAIR Impact Fund invests USD12m in Mutabilis and IBT Vaccines

The Novo Holdings REPAIR Impact Fund has made a EUR7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France. 

This investment will allow the company to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimisation.